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EDITORIAL Open Access
Intra-aortic balloon pump: is the tide
turning?
Sandro Gelsomino1,2* , Daniel M. Johnson2,3 and Roberto Lorusso1
Since the intra-aortic balloon pump (IABP) was used for
the first time by Kantrowitz et al. [1] there has been con-
troversy regarding its beneficial effects. In fact, even a re-
port where Kantrowitz himself is senior author states [2]:
… Precise indications for initiation and termination of
balloon counterpulsation remain in doubt.
However, after years of honest service, the IABP has
been struck by a scientific thunderstorm called “SHOCK
II”, which has seriously questioned the use of this assist
device in cardiogenic shock complicating acute myocar-
dial infarction [3]. After the initial “SHOCK” of this trial
there are still a number of questions remaining regard-
ing the utility of the IABP, as well as a number of differ-
ent “camps”. There are both the “storm riders”, who
have always believed that the IABP had limited use, and,
on the other side, the “honest IABP believers” who claim
that successful use of IABP counterpulsation has been
life-saving in many patients.
The majority of physicians, however, are in the middle,
finding themselves “between a rock and hard place”.
These physicians are overwhelmed by the fear of not ad-
hering to guidelines more than being really convinced of
the lack of benefit of IABP use [4, 5]. The net result of
this “hurricane” is that, in clinical practice in Europe and
the United States, the utilization rate of the IABP has
been decreasing over the last few years (Fig. 1).
Remaining neutral between the opposing views and
recognizing the unquestionable scientific value of the
SHOCK II trial, doubt has been raised on whether our
clinical convictions can be straightforwardly driven by
evidence coming just from a single randomized trial.
A number of recent studies have shown that there is
some sun on the horizon regarding use of the IABP. A
recent meta-analysis, for example, included 9212 patients
and investigated the utility of the IABP when implanted
preoperatively in patients undergoing coronary bypass
graft surgery [6]. The results of this analysis strongly indi-
cate that there is benefit in using the IABP under these
conditions, with the relative risk reduction of mortality
being more than 4%. Furthermore, the risk of MI and
renal failure were reduced when IABP treatment was
instigated and both intensive care and total hospital stays
were reduced, also indicating a possible economic benefit,
as well as health benefit, of using the IABP [6].
Likewise, a recent study by Yang et al. [7], carried out
in 416 patients with LV dysfunction undergoing off-pump
coronary bypass grafting, showed that a preoperative IABP
was linked with a lower 30-day mortality.
Interestingly, Iqbal et al. [8] recently carried out an
observational analysis of 174 patients (with 55 patients
receiving IABP) successfully resuscitated following an
out-of-hospital cardiac arrest. In this study, the use of
IABP therapy in the postresuscitation period was associ-
ated with improved functional recovery and outcomes,
although the mortality rate was not different between
the IABP and non-IABP groups [8].
Imamura et al. [9] recently showed that an elevation in
central venous pressure and a lower heart rate were a
predictor for significant hemodynamic response to IABP
treatment in a population of decompensated heart fail-
ure patients. A very recent study [10] indicated that the
IABP was associated with a lower risk of 30-day mortal-
ity in patients with acute myocardial infarction compli-
cated by cardiogenic shock, in whom percutaneous
coronary intervention was unsuccessful, whilst a higher
risk of death was seen in patients where PCI had been
successful. Taken together, these data indicate that im-
proved patient selection may greatly influence outcomes.
Interestingly, use of the IABP together with other sup-
port systems, such as extracorporeal membrane oxygen-
ation (ECMO), has also been receiving increased attention
over recent years [11]. For example, a recent study by
Meani et al. [12] showed the potential utility of the IABP
to reverse aortic valve closure and impaired left ventricular
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unloading that occurs during V-A ECMO support, whilst
Bréchot et al. [13] showed that the association of IABP
with V-A ECMO was associated with a lower frequency
of pulmonary edema. Further research, both at the
basic and the clinical level, is, however, required to fully
understand the utility of such combination therapy.
Is the tide turning? At this stage, it is too early to say
and we should be prudent, whilst at the same time critical,
when examining studies. Nevertheless, the heavy debate
on appropriate use of the IABP needs new lifeblood from
numerous avenues including cardiologists, intensivists,
anesthesiologists and cardiac surgeons. These specialties
need to work together to actively contribute to a rigorous
and objective data collection/examination/analysis. Fur-
thermore, a key role needs to be played by companies
involved in IABP development, who should, in our
opinion, show an interest in gaining new scientific
evidence to aid the scientific community in filling the
considerable gap currently existing between guidelines
and clinical practice.
In conclusion, maybe the time is right for new well-de-
signed clinical trials to cause an “After-SHOCK II” in
the field of IABP support. Only these data will properly
inform the community whether there is some nice wea-
ther on the horizon or whether we just have a temporary
rainbow.
Abbreviation
IABP: Intra-aortic balloon pump
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